Analysed CANDEL THERAPEUTICS INC (CADL:NASDAQ) News Sources
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
26-08-2026
yahoo.com
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
02-06-2026
yahoo.com
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’
30-06-2026
stocktwits.com
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
03-08-2026
yahoo.com
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
12-08-2026
marketbeat.com
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
12-08-2026
stocktwits.com
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
13-08-2026
stocktwits.com
What is the current price of CANDEL THERAPEUTICS INC (CADL:NASDAQ)?
The current price of CANDEL THERAPEUTICS INC (CADL:NASDAQ) is $13.07.
CANDEL THERAPEUTICS INC (CADL:NASDAQ) absolute price change since previous trading day?
The absolute price change of CANDEL THERAPEUTICS INC (CADL:NASDAQ) since the previous trading day is $-0.68.
CANDEL THERAPEUTICS INC (CADL:NASDAQ) percentage price change since previous trading day?
The percentage price change of CANDEL THERAPEUTICS INC (CADL:NASDAQ) since the previous trading day is -4.9455%.
What is the most recent average sentiment score for CANDEL THERAPEUTICS INC (CADL:NASDAQ)?
The most recent average sentiment score for CANDEL THERAPEUTICS INC (CADL:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for CANDEL THERAPEUTICS INC (CADL:NASDAQ)?
The most recent sentiment for CANDEL THERAPEUTICS INC (CADL:NASDAQ) is .
SEC-8K** Filing Available For CANDEL THERAPEUTICS INC (CADL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.